PSY-0.3

PSY-0.3 is a proprietary psilocybin/psilocin-based psychedelic formulation developed by Psilocin Pharma as part of its Hydroxy Line, specifically described as a gel cap dosage form alongside related capsule, sublingual spray, effervescent tablet, and transdermal formulations in the same series.[5][7][9] While detailed composition, dose, and pharmacokinetic modifications have not been publicly disclosed, PSY-0.3 is intended to deliver a controlled oral gelatin-capsule presentation of a psilocybin/psilocin-derived active ingredient for potential therapeutic use in neuropsychiatric and related indications, leveraging the classical psychedelic mechanism of 5‑HT2A receptor–mediated modulation of cortical networks and consciousness that is characteristic of psilocybin and psilocin.[3][7][9] The program is at an early, preclinical or very early clinical development stage with no registered interventional trials specifically under the PSY-0.3 identifier, and public information focuses primarily on its place within Psilocin Pharma’s broader formulation pipeline rather than on defined clinical indications.[7][9]